
Index

- Acetylation (slow v. fast), 11
 research on, 100
 and susceptibility to arylamine-induced bladder cancer, 95
 tests for, 233
- AHH (see Aryl hydrocarbon hydroxylase inducibility)
- American Conference of Governmental Industrial Hygienists (ACGIH), 120
- Anemia
 from benzene, 72
 in glucose-6-phosphate dehydrogenase (G-6P-D) deficiency, 7, 90
 sickle cell, 51, 91
 in thalassemia, 91-92
- Arsenic (see Chemicals)
- Arylamines (see Chemicals)
- Aryl hydrocarbon hydroxylase (AHH) inducibility, 11, 19
 predictive value of, 18
 prevalence of, 19, 172
 research on, 110
 and susceptibility to lung cancer, 94-95
- Asbestos (see Chemicals)
- Assessment of occupational studies, 60-61
- Atomic Bomb Casualty Commission (see Radiation Effects Research Foundation)
- Benzene (see Chemicals)
- Body fluids
 in detection of genetic traits or abnormalities, 53-54
 mutagens in, 18, 75-77
- Cadmium (see Chemicals)
- Cancer (see also Carcinogenesis 6,19,25)
 acetylation and susceptibility to arylamine-induced, 9,7, 100-101
 arylhydrocarbonhydroxylase(AHH) inducibility and susceptibility to, 94-95, 100
 in atomic bomb survivors, 70-71
 and carbon oxidation ability, 96, 100
 in chemical, smelting, and gold mining workers, 72
 and defective DNA repair, 97
- Carbon oxidation ability, 11
 high prevalence of, 19, 172
 implications for occupational and environmental health, 96
 research on, 100
 and susceptibility to cancer, 96
- Carcinogenesis
 by arsenic, 71
 by arylamines, 95
 correlation with chromosomal aberrations and sister chromatid exchange (SCE), 69
 by epichlorohydrin, 72
 mutations in, 10, 52-53, 68-69
 by polycyclic aromatic hydrocarbons, 94
 by vinyl chloride monomer, 73
- Chemicals
 arsenic, 71-72
 arylamines, 11, 95, 100
 asbestos, 5, 23
 benzene, 19, 72, 121
 cadmium, 72-73
 carcinogenic, 52-53
 clastogens, 121
 differential susceptibility to, 11
 epichlorohydrin, 72
 ethylene oxide, 72
 genetic damage from, 10, 18, 46, 52-53
 hazardous, 24
 lead, 72-73
 occupational exposure to, 6, 24
 parathion, 97
 polycyclic aromatic hydrocarbons, 94
 uranium, 71
 vinyl chloride, 19, 73-74
 zinc, 73
- Cholinesterases, 97
- Chromosomal aberrations (see also Cytogenetic studies), 10, 18, 28, 35, 37
 from arsenic exposure, 71
 in atomic bomb survivors, 70-71
 background frequencies, 227-229 (table)
 from benzene exposure, 72
 from cadmium exposure, 73
 and carcinogenicity, 69
 disease and, 68-69
 from epichlorohydrin exposure, 72
 from ethylene oxide exposure, 72
 extra Y chromosome, 79
 in unexposed populations, 70
 from vinyl chloride monomer exposure, 73-74
- Chromosomes (see Chromosomal aberrations)
- Committee on the Biological Effects of Ionizing Radiation, 6, 25
- Congress
 acts of (see Legislation)
 House Committee on Science and Technology, 5, 23, 181
 options for (see Policy options)
- Cotton dust, 121
- Cytogenetic studies (see also Genetics), 11
 on atomic bomb survivors, 70-71
 associations between chromosomal aberrations and disease, 68-69
 chromosomal studies on groups, 69-70
 correlation between chromosomal aberrations, sister chromatid exchanges, and carcinogenicity, 69
 economic evaluation of, 159-160
 in exposure to chronic low radiation, 71
 purpose of, 28
 significance of sister chromatid exchanges, 47
 on unexposed populations, 70
 in the workplace, 35, 37
- Deoxyribonucleic acid (see DNA)
- Dermatological hypersusceptibility, 98

Diseases

- association with certain genetic traits, 11
- association with human leukocyte antigens (HLA), 19
- detection of increased risk, 27-29
- differential susceptibility to, 27
- economic costs of occupational, 5
- genetic damage and risk of, 10, 18-19
- health hazards in the workplace, 24-26
- use of genetic testing for prevention of, 7-8, 27-29

DNA (deoxyribonucleic acid)

- detection of damage in, 10, 18, 37, 78-79, 171
- diseases of repair of, 11, 96-97
- role in protein synthesis, 48-49
- structure of, 48
- unscheduled synthesis of, in lymphocytes, 78

Down's syndrome, 46**Economic issues, 5, 13-14**

- benefits and risks, 29
- biases and value judgments, 153-154
- cost-benefit analyses, 151-152
- cost-effectiveness analyses, 152
- elements of economic evaluation, 154-156
- evaluation of cytogenetic monitoring, 159-160
- evaluation of genetic screening, 156-159
- identifying and measuring consequences, 152-153

EEOC (see Equal Employment Opportunity Commission)**Emphysema, 19, 93-94, 101****Environmental Protection Agency (EPA)**

- estimate of workplace exposure to ionizing radiation, 25
- federally funded data bank for epidemiologic studies, 19, 172

Gene-Tox Program, 19, 69, 172**inventory of hazardous chemicals, 6****research to develop better genetic tests, 18, 171****EPA (see Environmental Protection Agency)****Epidemiologic studies (see Research, epidemiologic studies in occupational settings)****Equal Employment opportunity Commission (EEOC), 123, 125****Erythrocyte catalase deficiency, 98****Ethical issues, 13**

- autonomy principle, 142-143
- Code of Ethics for Physicians Providing Occupational Medical Services, 117, 147
- compensation of genetically disadvantaged workers, 146
- dubious tests, 144-145
- high correlation between genetic endpoints and disease risk, 145-146
- informed consent, 145, 148
- justice, 143-144
- in medical research, 145
- nonmaleficence and beneficence, 143

Fortune 500" companies, 37, 38, 39**G-6 P-D (see Glucose-6-phosphate dehydrogenase deficiency)****Genetics (see also Cytogenetic studies)**

- and ability to detoxify chemicals, 50
- alleles, 49, 50, 51, 52
- as basis of human variability, 49-50

body fluids used in detection of traits or abnormalities, 53-54

of cancer, 52-53

cell division, 45

chromosome] aberrations, 46-47

chromosome] instability diseases, 52

DNA damage, 47, 51

DNA repair, 53

Down's syndrome, 46

of erythrocyte catalase deficiency, 98

genotype, 52

heterozygosity, 51-52

homozygosity, 51

immunoglobulin A deficiency, 97

interaction with physiological processes, 89

karyotyping, 45-46

metabolism of chemical agents, 53

mutations, 51, 52-53, 68-69

paraoxanase polymorphism, 97

phenotype, 52

polygenic traits, 52

pseudocholinesterase variants, 98

of red blood cell traits, 89-93

sickle cell anemia, 51

single gene traits, 51-52

sister chromatids, 4, 5, 47

of superoxide dismutase, 97

of Tay-Sachs disease, 51

variant genes, 49-50

Gene-Tox Program (see Environmental Protection Agency, Gene-Tox Program)**Germ cell damage, 79****Glossary, 237-238****Glucose-6-phosphate dehydrogenase (G-6P-D) deficiency, 7, 11**

characteristics of, 90-91

frequency of testing for, in industry, 34

hypothetical distribution of, 58 (figure)

research on, 100

tests for, 233

and worker susceptibility, 27, 90-91

Health hazards

control of, 25-26

types found in the workplace, 24-26

Hemoglobin

alkylated, 18, 171

mutations, 18, 171

HGPRT mutation in lymphocytes, 18**HLA (see Human leukocyte antigens)****Human leukocyte antigens (HLA), 11**

and risk of disease, 19, 96, 172

tests for, 233

Immunoglobulin A deficiency, 97**industrial companies, 33****Insecticides, 98****Ionizing radiation**

diseases caused by, 19, 25

effects in atomic bomb survivors, 70-71

- genetic damage from, 10-11, 18, 46
occupational exposure to, 6, 25, 71
- Lactic dehydrogenase-X (LDH-X)
 automated testing for, 79, 171
- LDH-X (see Lactic dehydrogenase-X)
- Lead (see Chemicals)
- Legal issues (see also Litigation), 11-13
 business necessity and job relatedness of genetic testing, 124-125, 128-130
 confidentiality of medical records, 117-118
 disclosure of health risks, 117
 duty to conduct medical or genetic testing, 116
 employee access to records, 117, 123
 employer liability, 113-114
 employer rights and duties, 11, 112, 119
 genetic testing and the general duty clause of the OSHA Act, 120
 genetic testing and OSHA standards, 121
 informed consent, 116-117
 medical removal protection and rate retention, 122-123
 racial and ethnic distribution of testable genetic traits, 124
 reasonable accommodation for susceptible employees, 130
 regulation of company medical and employment practices, 118-130
 relationship of company doctors to employers and employees, 115
 right to refuse examination, 116, 125-126
 right to refuse hazardous work, 119
 State and Federal antidiscrimination laws on hiring the handicapped, 126-130
 testing solely for research, 116
 variable susceptibility of employees in standards setting, 120-121
 worker's compensation laws, 112-113
- Legislation
 Bankruptcy Act, 23
 Civil Rights Act, 12111, 118, 123-126
 Confidentiality of Medical Information Act (Calif.), 118
 National Labor Relations Act (NLRA), 111
 National Research Act, 116
 Occupational Safety and Health Act (OSH Act), 11-12, 111, 117, 118, 119-123, 143
 Rehabilitation Act, 12-13, 17, 126-130
- Leukemia, 68
 in atomic bomb survivors, 70
 from benzene exposure, 72
 from ethylene oxide exposure, 72
- Litigation
 Arlene Paper Co. v. Moody, 124, 125, 129
 American Textile Manufacturers Institute v. Donovan (Cotton Dust case), 121, 122-123
 on asbestos, 23
 Bednarski v. General Motors, 113
 Benzene case (see *Industrial Union Department, 4 FL-CIO v. American Petroleum Institute*)
 Borel v. Fibreboard Paper Products Corp., 114
 Cotton Dust case (see *American Textile Manufacturers Institute v. Donovan*)
 Griggs v. Duke Power Co., 123-124
 Industrial Union Department, 4 FL-CIO v. American Petroleum Institute (Benzene case), 121
 Mandolidas v. Elkins Industries, Inc., 114
 OFCCP v. E.E. Black, Ltd., 127-128
 Whirlpool Corp. v. Marshall, 119
 Low-activity paraoxanase, 97
 Lymphocyte transformation assay, 79
- Methemoglobinemia, 92-93
- Monitoring for genetic changes
 as aid in identifying hazardous substances, 10-11
 in atomic bomb survivors, 10
 cytogenetic, 67-75, 159-160
 economic evaluation, 159-160
 epidemiologic studies using, 19
 ethical issues in, 145, 147
 v. genetic screening, 5, 7-8, 23, 57
 methodology, 10-11, 26, 37
 none, to genetic, 18, 75-80
 validity and reliability of, 28
- Mutagens
 binding to hemoglobin, 77
 in body fluids, 18, 75-77
 in feces, 77
 monitoring of mutations from, 10
- NADH dehydrogenase deficiency, 11
 characteristics of, 92-93
 tests for, 233
- National Institute for Environmental Health and Safety (NIEHS)
 epidemiologic studies in occupational settings, 171-172
 federally funded data bank for epidemiologic studies, 19, 172
 research to develop better genetic tests, 18, 171
- National Institute for Occupational Safety and Health (NIOSH)
 epidemiologic studies in occupational settings, 171-172
 estimate of worker exposure to hazardous chemicals, 6
 federally funded data bank for epidemiologic studies, 19, 172
 National Occupational Hazard Survey (NOHS), 24
 research to develop better genetic tests, 18, 171
- National Labor Relations Board, 12
- National Occupational Hazard Survey (NOHS), 24
- National Opinion Research Center (NORC)
 survey of genetic testing by industry, 9, 33, 175-226
- NIEHS (see National Institute for Environmental Health and Safety)
- NIOSH (see National Institute for Occupational Safety and Health)
- NOHS (see National Occupational Hazard Survey), 24
- NORC (see National Opinion Research Center)
- Nuclear industry, 6
- Occupational Safety and Health Administration (OSHA), 12, 24
 Access to Employee Exposure and Medical Records Standard, 117, 118
 exposure standard for ethylene oxide, 72
 threshold limit standards adopted by, 120

- Office of Technology Assessment (OTA)
 assessment of occupational studies, 60-61
 contributors and contractors (this report), 235-236
 survey of genetic testing by industry, 9, 23, 33-40, 175-226
- OSHA (see Occupational Safety and Health Administration)
- OSH (see Legislation, occupational Safety and Health Act)
- OTA (see Office of Technology Assessment)
- Paraoxanase polymorphism, 97
- Parathion (see Chemicals)
- Policy options
 adopt Federal regulations on protection of human research subjects, 170
 constrain employment actions based on genetic testing, 169-170
 employers to disclose nature and purpose of medical procedures, 170-171
 employers to demonstrate predictive ability of tests, 170
 encourage voluntary guidelines, 16
 Federal funding of research, 171-172
 maintain the status quo, 14, 167
 prohibit genetic testing in the workplace, 15-16, 168-169
 regulate genetic testing, 16-18, 169-171
 stimulate genetic testing technology, 15, 18-19, 167-168
- Polycyclic aromatic hydrocarbons (see Chemicals)
- Predictability' (see Validity, reliability, predictive value)
- Protein synthesis, 48-49
- Pseudocholinesterase variants, 98
- Purposes of genetic testing, 27-28, 35, 36, 38-39
- Radiation Effects Research Foundation, 70
- Radiation (see Ionizing Radiation)
- Red cell phosphatase distribution, 99 (figure)
- Regulation (see Policy options)
- Reliability (see Validity, reliability, predictive value)
- Research
 to develop better genetic tests, 18
 by employers on employees, 17
 epidemiologic studies in occupational settings, 18-19, 171-172
 federally funded data bank for epidemiologic studies, 19, 172
 priorities, 19, 74-75, 80, 100-101, 172
- Respiratory tract infections, 97
- Risk determination, 7-8, 27-28, 59-60
- SAT (see Serum alpha₁-antitrypsin deficiency)
- SCE (see Sister chromatid exchanges)
- Screening for genetic traits
 accuracy and reliability of tests in, 11
 acetylation and susceptibility to arylamine-induced bladder cancer, 95-96
 adverse drug reactions and risk of disease from occupational exposures, 11
 arylhydrocarbon hydroxylase inducibility and susceptibility to lung cancer, 94-95
 carbon oxidation ability, 96
 H₂O₂ sensitivity/hypersusceptibility, 96
 diseases of DNA repair, 96-97
 economic evaluation of, 156-159
 erythrocyte catalase deficiency and sensitivity to hydrogen peroxide producing agents, 96
 ethical issues in, 144-145, 146
 v. genetic monitoring, 5, 7-8, 23, 28, 57
 glucose-6-phosphate dehydrogenase (G-6P-D) deficiency and hemolytic anemia, 90-91
 human leukocyte antigens (HLA) associated with disease susceptibility, 96
 immunoglobulin A deficiency and risk of respiratory tract infections, 97
 lung disease, 93-95
 NADH dehydrogenase deficiency and methemoglobinemia, 92-93
 paraoxanase polymorphism and risk of parathion toxicity, 97
 pseudocholinesterase variants and sensitivity to insecticidal compounds, 98
 red blood cell traits, 89-93, 100
 research on, 100-101
 reservations in application of, 99
 selection of employees for, 34-36
 serum alpha₁-antitrypsin deficiency' and susceptibility to emphysema, 93-94
 sickle cell trait and sickle cell anemia, 91
 superoxide dismutase, 97
 tests in current use, 36-37, 233
 thalassemias and erythroblastic anemia, 91-92
 traits measured in, 11, 19, 89-101
- Secretary of Labor, 11, 12
- Sensitivity and specificity of tests, 58
- Serum alpha₁-antitrypsin (SAT) deficiency, 11, 19
 characteristics of, 93-94
 economic evaluation of testing for, 157-158
 frequency of use in industry, 34
 high prevalence of, 19, 172
 hypothetical break-even number of cases averted by testing for, 157 (table)
 research on, 101
 and susceptibility to emphysema, 93-94
 tests for, 233
- Sickle cell trait, 9, 34
 beta-S globin and, so
 d incrimination based on, 12
 prevalence and distribution of, 91
 screening for, 11, 34, 38, 91
 tests for, 233
- Sister chromatid exchanges (SCE)
 background frequencies, 231 (table)
 and carcinogenicity, 69
 definition, 47
 testing in industry, 35, 37
 in unexposed populations, 70
- Spondylitis, ankylosing, 96
- State of the art (genetic testing), 9-10, 67-101
- Super' oxide dismutase alleles, 97
- Survey of genetic testing, 9, 23, 33-40
 analysis of nonrespondents, 205-208
 animal testing, 196
 comments on questionnaire, 202-203
 factors and criteria for test selection, 201 (table)

- literature review, 185-188
 - methodology, 181-184
 - missing data, 191
 - questionnaire, 175-176
 - rates of testing reported, 194, 195 (table)
 - response patterns, 176-178, 189-190, 192-193 (table)
 - response quality, 190
 - results of testing reported, 199-200
 - source of data, 175
 - study conclusions, 203-204
 - survey materials, 209-226
 - types of testing reported, 197-199
- Tay-Sachs disease, 51
- Thalassemias, 11
- characteristics of, 91-92
 - tests for, 233
- Theoretical foundations (of genetic testing), 7, 27, 45-54
- ‘111. roiddisease, 96
- Unions, 11, 33
- University of Chicago, 9, 33
- Uranium (*see* Chemicals)
- Utilities, 33
- Validity, reliability, predictive value (of genetic tests), 11, 28, 57-59
- calculation of predictive value, 59 (table)
 - influence of genotype frequency on predictive value of screening tests, 59 (table)
- Vinyl chloride (*see* Chemicals)
- Zinc (*see* Chemicals)

